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Emergence of Plasmodium falciparum resistance to antimalarial drugs is currently the primary rationale 54 supporting the development of new and well-tolerated drugs. While the estimated number of malaria cases 55 in the world decreased from 237 million (218-278 million) in 2010 to 211 million (192-257 million) in 56 2015, the morbidity and the mortality have stabilized in 2016 with estimates of 216 million cases (196-263 57 million) and 445,000 deaths (compared to 446,000 in 2015) as reported by the WHO (1-3). Globally, the 58 vast majority of deaths (>90%) caused by malaria is due to P. falciparum infections occurring in Africa, 59
children under five years of age. Artemisinin Combination Therapies (ACTs) which are currently 60 recommended as first-line treatment of uncomplicated falciparum malaria, are less effective in Southeast 61
Asia, particularly in Cambodia, where high rates of treatment failure associated with artemisinin and 62 piperaquine resistance are currently reported (4-16). The containment and the elimination of these 63 multidrug resistant parasites in Southeast Asia are a priority for the WHO to avoid their spread to Africa as 64 was the case with previous generations of antimalarial drugs (e.g. chloroquine, sulfadoxine-pyrimethamine) 65 (17). Fortunately, molecular markers associated with such resistance are available (10). In particular, 66 mutations in the propeller domain of a Kelch gene located on the chromosome 13 (Kelch13), and 67 amplification of a cluster of genes encoding both Plasmepsin 2 (Pfpm2) and Plasmepsin 3 proteins, have 68 been recently shown to be associated with artemisinin and PPQ resistance, respectively (18) (19) (20) . 69
According to the latest WHO update on artemisinin resistance (21), to be validated a Kelch13 resistance 70 mutant has to be correlated with delayed parasite clearance in clinical studies and reduced drug in vitro 71 susceptibility (survival rate ≥ 1% expressed by the Ring-stage Survival Assay, RSA0-3h) in fresh isolates 72 (ex vivo assays), or culture-adapted field parasites or Kelch13 genome-edited parasites (in vitro assays) (22-73 25) . To date, only five Kelch13 mutations are validated (C580Y, Y493H, R539T, I543T, N458Y). The 74 F446I mutant, which is highly prevalent in Myanmar, is strongly suspected of being associated to 75 artemisinin resistance. In Africa, a broad array of rare non-synonymous mutations in the Kelch13 gene have 76 been described in P. falciparum isolates, but any of these mutants have not been associated with artemisinin 77 resistance (26), attesting that not all non-synonymous Kelch13 mutations confer resistance to artemisinin. 78
More recently, resistance to PPQ has been associated with an increase of survival rates of parasite exposed 79 to 200 nM PPQ for 48 hours (piperaquine survival assay, PSA) and with the amplification of plasmepsin 80 2-3 genes (Pfpm2-3) (6, 20) . In Cambodia, where high rates of treatment failure to dihydroartemisinin-81 piperaquine (DHA-PPQ) are observed (i.e. >60% in some provinces), it has been demonstrated that 82 amplification of Pfpm2 gene and presence of validated Kelch13 mutations were highly predictive of DHA-83 PPQ treatment failure (20) . Most of these parasites harbor a single copy of Pfmdr1 gene leading to the 84 recovery of mefloquine sensitivity (4, 6) and suggesting a natural antagonism between PPQ resistance and 85 mefloquine resistance. However, we still do not understand whether Pfmdr1 de-amplification (from 86 multiple copies to single copy Pfmdr1) is due to the implementation of DHA-PPQ as first-line treatment or 87 due to the release of mefloquine pressure and an increase in parasite fitness accompanying Pfmdr1 gene 88 de-amplification. To date, DHA-PPQ resistance is confined to Southeast Asia. Only a recent study 89 conducted in Mozambique has provided evidence of the presence (at a very low frequency, 1.1%) of 90 parasites carrying multiple copies of Pfpm2 (27) were observed: A578S was the most predominant Kelch13 mutation (7/10; 3 in Uganda, 2 in Gabon, 1 in 151
Mozambique and 1 in Burkina Faso) followed by Y541F, M562T and A626V (only detected once in isolates 152 from Burkina Faso). 153
Isolates from Uganda and Burkina Faso showed an unexpected high frequency of parasites with multiple 154 copies of Pfpm2 (34.0%, 38/112, 32/105, (32-34) compared to Africa (35-37). These finding likely reflect the profiles of evolution of P. falciparum 189 populations linked to antimalarial drug pressure in both continents. Especially, the prevalence of high 190
Pfmdr1 amplification observed in Africa might be linked with the routine use of artemether-lumefantrine 191 as first line treatment for more than a decade. Indeed, increased pfmdr1 copy number is known to modulate 192 parasite responses to a wide range of drugs including lumefantrine (35, 38, 39) . Supporting this expectation, 193 it seems feasible that such parasites exposed to lumefantrine as monotherapy for several days following 194 clearance of artemether have been selected, while parasites with a single copy have been eliminated. In 195 contrast, the low prevalence of Pfmdr1 multiple copies observed in Southeast Asia could be due to the 196 recent implementation of DHA-PPQ, the removal of the mefloquine drug pressure or both, as the case in 197
Cambodia (18, 20, 40) . Unexpectedly, in African isolates, amplification of Pfpm2 gene was shown to occur at a much higher 205 frequency (~27% on average across clinical sites in Africa, reaching 30.5% in Burkina Faso and 33.9% in 206 Uganda) than was recently described (from 11.1% to 13.8% in Uganda and 1.1% in Mozambique) (27, 41) . 207
Considering the geographical extent and the diversity of the clinical sites in Africa, the high frequency 208 reported at sites distant to each other suggests that amplification of Pfpm2 gene occurred independently in 209 each site. More importantly, since in Southeast Asia most parasites with multiple copies of Pfpm2 also 210 display Kelch13 resistance mutations, which is not the case in African samples, it is likely that Pfpm2 211 amplification originated in Africa, independently of Southeast Asia. 212 213 Unfortunately, we were not be able to perform in vitro or ex-vivo drug susceptibility assays and test 214 association between Pfpm2 amplification and clinical resistance to PPQ in the current study. An evaluation 215 is currently ongoing to see whether, and if so to what extent, these markers of artemisinin and PPQ 216 resistance affected the parasite clearance half-life (PCT1/2) and PCR-adjusted 28 days follow up in patients 217 treated with artefenomel/PPQ (study MMV OZ439 13 003). However, it was recently reported that 218 compared to drug sensitivities measured on Ugandan isolates from 2010 to 2013 (from the same site, 219 namely Tororo), those measured in 2016 to chloroquine, amodiaquine, and PPQ were increased by 7.4, 5.2 220 and 2.5-fold respectively (41). This longitudinal study showed that rather than drug resistance developing 221 to these three antimalarial drugs, an increase in sensitivity was observed that was correlated with low 222 prevalence of the polymorphisms recently associated with resistance to artemisinins or PPQ. Kelch13 gene (PF3D7_1343700) that have recently been associated with artemisinin resistance (19) . 268
Amplification of the Kelch-propeller domain (codons 440-680, 720 bp) was performed as previously 269 described (26). Cross-contamination was evaluated by adding no template samples (dried blood spots 270 negative for P. falciparum) in each PCR run. PCR products were sequenced by Macrogen (Seoul, Korea). 271
Electropherograms were analysed on both strands, using PF3D7_1343700 as the reference sequence. The 272 quality of the procedure was assessed by including dried blood spots with known Kelch13 mutations (wild-273 type, C580Y, R539T, I543T, Y493H) which were tested blindly in the same batches (each 96-well) with 274 the test samples. Isolates with mixed alleles were considered as mutant. Following the WHO 275 recommendations, Kelch13 mutants were classified in our study in three groups: wild-type group (parasites 276 with no synonymous or non-synonymous mutations compared to 3D7 sequence), Kelch13 validated 277 (N458Y, Y493H, R539T, I543T, C580Y) and candidate mutation (P441L, F446I, G339A, P553L, V568G, 278 P574L, A675V) group, and other Kelch13 mutants group (parasites with synonymous or non-synonymous 279 mutations not present in the Kelch13 validated and candidate resistance mutation group). 280 281 Pfpm2 and Pfmdr1 genes copy number variation assessment 282 Pfpm2 (PF3D7_1408000) and Pfmdr1 (PF3D7_0523000) genes copy number were measured by qPCR 283 using a CFX96 real-time PCR machine (Bio-Rad, France), relative to the single copy of the β-tubulin gene 284 (used as reference gene), as previously described (20). Amplification was carried out in triplicate. In each 285 amplification run, six replicates using DNA from 3D7 parasite reference clone and three replicates without 286 template (water) used as negative controls were included. Copy numbers were calculated using the formula: 287 copy number= 2 −ΔΔCt ; with ΔΔC t denoting the difference between ΔC t of the unknown sample and ΔC t of 288 the reference sample (3D7). Specificities of Pfpm2 and Pfmdr1 amplification curves were evaluated by 289 visualizing the melt curves. Multiple copies vs single copy, of both Pfmdr1 and PfPm2, were defined as 290 copy numbers <1.5 and ≥1.5 respectively. 291
292
Statistical analysis 293
Data were recorded and analyzed using Excel software and MedCalc (MedCalc Software, Belgium). 294
Groups were compared using the Chi squared test or the Fisher's exact test. All reported P-values are two-295 sided and were considered statistically significant if <0.05. 296
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